BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009;94:1029-1032. [PMID: 19454500 DOI: 10.3324/haematol.2008.001925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-naharro A, Quarta C, Hawkins PN, Wechalekar AD. A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol 2019;187:642-52. [DOI: 10.1111/bjh.16143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
2 Wang Y, Zhao C, Yin H. Primary hepatic amyloidosis: a mini literature review and five cases report. Annals of Hepatology 2012;11:721-7. [DOI: 10.1016/s1665-2681(19)31450-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
3 Takayasu V, Laborda LS, Bernardelli R, Pinesi HT, Silva MP, Chiavelli V, Simões AB, Felipe-Silva A. Amyloidosis: an unusual cause of portal hypertension. Autops Case Rep 2016;6:9-18. [PMID: 27547738 DOI: 10.4322/acr.2016.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Cichoż-Lach H, Prozorow-Król B, Swatek J, Skrzydło-Radomańska B, Buk L, Zdunek M, Kowalik A, Słomka M. Hepatomegaly, weight loss and general malaise - the first manifestations of primary systemic amyloidosis. Prz Gastroenterol 2014;9:57-61. [PMID: 24868301 DOI: 10.5114/pg.2014.40853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
5 Munoz J, Janakiraman N. Relapse of liver amyloidosis 6 years after autologous stem cell transplantation. Am J Hematol 2012;87:926. [PMID: 22641527 DOI: 10.1002/ajh.23242] [Reference Citation Analysis]
6 Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 2018;4:38. [PMID: 30361521 DOI: 10.1038/s41572-018-0034-3] [Cited by in Crossref: 146] [Cited by in F6Publishing: 129] [Article Influence: 36.5] [Reference Citation Analysis]
7 Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biol Blood Marrow Transplant 2015;21:1445-51. [PMID: 25858810 DOI: 10.1016/j.bbmt.2015.04.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
8 Abe R, Katoh N, Takahashi Y, Takasone K, Yoshinaga T, Yazaki M, Kametani F, Sekijima Y. Distribution of amyloidosis subtypes based on tissue biopsy site - Consecutive analysis of 729 patients at a single amyloidosis center in Japan. Pathol Int 2021;71:70-9. [PMID: 33112446 DOI: 10.1111/pin.13041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, Carrier P, Lefebvre A, Bordessoule D, Vidal E. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011;18:19-24. [PMID: 21219116 DOI: 10.3109/13506129.2010.543443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tang SH, Zeng WZ, Wu XL, Qin JP, Chen YH, Cheng SP, Liang Y, Jiang MD. Hepatic amyloidosis: Clinical characteristics and follow-up. Shijie Huaren Xiaohua Zazhi 2014; 22(30): 4634-4637 [DOI: 10.11569/wcjd.v22.i30.4634] [Reference Citation Analysis]
11 Liu YP, Liu X, Zhang KX, Zhao JT, Huang M. Primary hepatic amyloidosis: A case report. Shijie Huaren Xiaohua Zazhi 2012; 20(31): 3065-3067 [DOI: 10.11569/wcjd.v20.i31.3065] [Reference Citation Analysis]
12 Muhammad Khan M, Ur Rashid M, Ullah W, Hussain I, Hurairah A. Rare case of acute on chronic hepatic failure in a patient with multiple myeloma-associated amyloidosis. BMJ Case Rep 2020;13:e231563. [PMID: 31996385 DOI: 10.1136/bcr-2019-231563] [Reference Citation Analysis]
13 Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia 2021;35:916-9. [PMID: 32737434 DOI: 10.1038/s41375-020-1006-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sanchorawala V. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am 2014;28:1131-44. [PMID: 25459183 DOI: 10.1016/j.hoc.2014.08.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
15 Guo YM, Takahashi N, Miyabe K, Yoshida M, Abe F, Yamashita T, Nara M, Yoshioka T, Ohashi K, Goto A, Takahashi N. Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency. Intern Med 2019;58:3039-43. [PMID: 31243220 DOI: 10.2169/internalmedicine.2864-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Hasan SM, Ahmed NN, Ahmed Z, Seibert A. Response of Bortezomib Chemotherapy in Hepatic Amyloidosis. J Investig Med High Impact Case Rep 2018;6:2324709618760079. [PMID: 29552568 DOI: 10.1177/2324709618760079] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]